Literature DB >> 11385690

BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma.

T Knutson1, C Edlund, M Fall, C Dahlstrand.   

Abstract

The aim of this study was to use a systematic schedule, including urodynamics, to describe the rate of coexisting overactive bladder (OB) in patients with bladder outlet obstruction (BOO) caused by benign prostatic hyperplasia (BPH). We also identified differences between the patients with pure BOO compared with those with BOO combined with OB (BOO + OB). One hundred and sixty-two men referred to our clinic due to LUTS were included. Patients with a history that might affect their bladder function were excluded. After cystometry and pressure-flow studies, the patients were divided into pure BOO and BOO + OB. Of the 162 men, 55% had pure BOO. BOO + OB was found in 45%. Age, s-PSA, voided volume, and obstruction grade differed significantly between the groups. The patients with BOO + OB were older, had a higher s-PSA, voided smaller volumes, and were more obstructed. We found no differences in TRUS-volume, Q-max, IPS score, or PVR. There was a strong association between OB and BOO, the percentage of OB increasing with increased obstruction. TRUS-volume, Q-max, IPS score, and PVR did not predict whether the patients had a combined BOO + OB or not. These findings indicate that BOO is a progressive disease, which in time causes pronounced obstruction and perhaps in itself contributes to the development of OB.

Entities:  

Mesh:

Year:  2001        PMID: 11385690     DOI: 10.1002/nau.1001

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  29 in total

1.  Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2006

Review 2.  Models of inflammation of the lower urinary tract.

Authors:  Dale E Bjorling; Zun-Yi Wang; Wade Bushman
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

Review 3.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

4.  Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.

Authors:  Andrea Tubaro; José E Batista; Victor W Nitti; Sender Herschorn; Christopher R Chapple; Mary Beth Blauwet; Emad Siddiqui; Moses Huang; Matthias Oelke
Journal:  Ther Adv Urol       Date:  2017-05-10

5.  Age-related urologic problems in the complex urologic patient.

Authors:  Nicholas Faure Walker; Bradley Gill; Jonathan Olsburgh; David Gillatt; Tet Yap; Lina Michala; Claire Taylor; Hadley Wood; Dan Wood
Journal:  World J Urol       Date:  2020-02-15       Impact factor: 4.226

6.  The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.

Authors:  Seung Hwan Lee; Dae Kyung Kim; Joon Chul Kim; Kyu-Sung Lee; Jeong Gu Lee; Choal Hee Park; Sung Joon Hong; Choung-Soo Kim; Jong Kwan Park; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

7.  Non-invasive parameters predicting bladder outlet obstruction in Korean men with lower urinary tract symptoms.

Authors:  Min-Yong Kang; Ja Hyeon Ku; Seung-June Oh
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

Review 8.  Place of overactive bladder in male lower urinary tract symptoms.

Authors:  Osamu Yamaguchi; Ken Aikawa; Keiichi Shishido; Masanori Nomiya
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

Review 9.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

10.  Prevalence, evaluation and management of overactive bladder in primary care.

Authors:  Wellman W Cheung; Nadia H Khan; Karmina K Choi; Martin H Bluth; Miriam T Vincent
Journal:  BMC Fam Pract       Date:  2009-01-23       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.